Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
---|
04/09/2013 | US8415338 Oxygen linked pyrimidine derivatives |
04/09/2013 | US8415336 Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals |
04/09/2013 | US8415335 Methods of treating hypertriglyceridemia |
04/09/2013 | US8415334 Method of combating infection |
04/09/2013 | US8415333 Bronchodilating diazaheteroaryls |
04/09/2013 | US8415332 A female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days to provide contraceptive and non-contraceptive benefits; reduce bleeding problems; multiphase adminstering with variation in dosage; ethinyl estradiol |
04/09/2013 | US8415331 Doxycycline metal complex in a solid dosage form |
04/09/2013 | US8415330 Biological specimen collection and transport system and method of use |
04/09/2013 | US8415329 Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations |
04/09/2013 | US8415328 Factor VIIa inhibitor |
04/09/2013 | US8415327 Methods of and compositions for reducing cell death |
04/09/2013 | US8415326 Pharmaceutical composition comprising chito-oligomers |
04/09/2013 | US8415325 Cell-mediated delivery and targeted erosion of noncovalently crosslinked hydrogels |
04/09/2013 | US8415324 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions |
04/09/2013 | US8415323 MicroRNAs for inhibiting viral replication |
04/09/2013 | US8415322 Modified fluorinated nucleoside analogues |
04/09/2013 | US8415321 Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections |
04/09/2013 | US8415313 Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
04/09/2013 | US8415312 Compound which is a nystatin derivative |
04/09/2013 | US8415311 Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
04/09/2013 | US8415310 Isoxazoline derivatives as antiparasitic agents |
04/09/2013 | US8415309 Bicyclic nucleosides and nucleotides as therapeutic agents |
04/09/2013 | US8415308 1′-substituted-carba-nucleoside prodrugs for antiviral treatment |
04/09/2013 | US8415304 Sparc and methods of use thereof |
04/09/2013 | US8415303 Method of treatment using a soluble human delta protein fragment |
04/09/2013 | US8415297 Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
04/09/2013 | US8415295 Heterocyclic boronic acid compounds |
04/09/2013 | US8415159 Tissue scaffolds derived from forestomach extracellular matrix |
04/09/2013 | US8414927 Biodegradable; drug delivery |
04/09/2013 | US8414922 Sublingual films |
04/09/2013 | US8414920 Pharmaceutical composition containing irbesartan |
04/09/2013 | US8414918 Stable imatinib compositions |
04/09/2013 | US8414915 Dual action, inhaled formulations providing both an immediate and sustained release profile |
04/09/2013 | US8414913 Edible compositions for lowering cholesterol |
04/09/2013 | US8414911 Photochemical therapy to affect mechanical and/or chemical properties of body tissue |
04/09/2013 | US8414910 Drug releasing coatings for medical devices |
04/09/2013 | US8414909 Such as a balloon catheter or a stent; a drug not enclosed in micelles or encapsulated in particles or controlled release carriers and an additive having hydrophobic and hydrophilic portions; improved pharmacokinetics and bioavailability |
04/09/2013 | US8414895 Tweak receptor |
04/09/2013 | US8414894 Human antibodies that bind human TNFα and methods of using same |
04/09/2013 | US8414874 Has absorbable, amphiphilic, solid copolyester stent coating composition; contains bioactive compounds and a copolymerization product of polyalkylene glycol |
04/09/2013 | US8414873 Blood vessel stent of amidoglucosan polysaccharide loaded with CD133 antibody and its preparation method |
04/09/2013 | US8414768 Citrate-based dialysate chemical formulations |
04/09/2013 | US8414525 Drug releasing coatings for medical devices |
04/09/2013 | CA2749172C Re-epithelializing pharmaceutical compositions comprising xanthan gum |
04/09/2013 | CA2746788C Modafinil polymorphic forms |
04/09/2013 | CA2740659C Novel compound containing vanillin and ethylvanillin, and preparation and applications thereof |
04/09/2013 | CA2737565C N-phenyl-2-pyrimidine-amine derivatives |
04/09/2013 | CA2695605C Pyrazolone derivative emulsion formulations |
04/09/2013 | CA2694277C Stable formulations of thiadiazole derivatiive |
04/09/2013 | CA2692004C Methods and compositions to inhibit edema factor and adenylyl cyclase |
04/09/2013 | CA2659590C Irreversible protein tyrosine kinases inhibitors and the preparation methods and uses thereof |
04/09/2013 | CA2656356C Antiviral phosphinate compounds |
04/09/2013 | CA2651604C Method for preparation of substantially amorphous telmisartan |
04/09/2013 | CA2619111C Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
04/09/2013 | CA2611147C Topical emulsion formulation |
04/09/2013 | CA2601935C Nk1 antagonists |
04/09/2013 | CA2601501C Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
04/09/2013 | CA2588881C Potentiators of glutamate receptors |
04/09/2013 | CA2587642C Substituted heterocycles and methods of use |
04/09/2013 | CA2581927C Treatment or prevention of unscheduled bleeding in women on progestogen containing medication |
04/09/2013 | CA2573543C N-phenylphosphoric acid triamides, method for the production thereof and their use as agents for regulating or inhibiting enzymatic urea hydrolysis |
04/09/2013 | CA2572833C Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
04/09/2013 | CA2569827C Quinazolinedione derivatives as parp inhibitors |
04/09/2013 | CA2566601C Carboxamido opioid compounds |
04/09/2013 | CA2566431C Process for the preparation of telmisartan |
04/09/2013 | CA2561555C Bicyclic aromatic sulfinyl derivatives |
04/09/2013 | CA2536436C 2-amido-4-aryloxy-1-carbonyl pyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
04/09/2013 | CA2531186C Use of an antioxidant in a dermatological and/or cosmetic composition |
04/09/2013 | CA2531050C Pharmaceutical compounds |
04/09/2013 | CA2527192C Novel imidazole derivatives, the production thereof, and the use of the same as a medicament |
04/09/2013 | CA2516471C Ferric organic compounds, uses thereof and methods of making same |
04/09/2013 | CA2513915C New arylpiperazinyl compounds |
04/09/2013 | CA2510785C Substituted amides |
04/09/2013 | CA2488230C Inositol pyrophosphates, and methods of use thereof |
04/09/2013 | CA2451116C Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms |
04/09/2013 | CA2450777C Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
04/09/2013 | CA2399219C Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase |
04/09/2013 | CA2241373C Compositions and methods for t-cell activation comprising gm-csf and tumor antigen fusion proteins |
04/09/2013 | CA2224176C Gene transfer for treating a connective tissue of a mammalian host |
04/04/2013 | WO2013049859A1 Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
04/04/2013 | WO2013049773A1 Antiviral therapies with phospholipase d inhibitors |
04/04/2013 | WO2013049770A2 Methods of treating cancer |
04/04/2013 | WO2013049726A2 Processes for making compounds useful as inhibitors of atr kinase |
04/04/2013 | WO2013049722A1 Compounds useful as inhibitors of atr kinase |
04/04/2013 | WO2013049720A1 Compounds useful as inhibitors of atr kinase |
04/04/2013 | WO2013049719A1 Compounds useful as inhibitors of atr kinase |
04/04/2013 | WO2013049701A1 Certain chemical entities, compositions, and methods |
04/04/2013 | WO2013049686A1 Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
04/04/2013 | WO2013049617A1 Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound |
04/04/2013 | WO2013049585A1 Arylsubstituted thiazolotriazoles and thiazoloimidazoles |
04/04/2013 | WO2013049581A1 Compositions and methods for the treatment of proliferative diseases |
04/04/2013 | WO2013049567A1 Compounds for the treatment of mycobacterial infections |
04/04/2013 | WO2013049565A1 Imidazole derivatives as cyp17 inhibitors for the treatment of cancer |
04/04/2013 | WO2013049559A1 Pyridine derivatives |
04/04/2013 | WO2013049523A1 Methods for reducing a-beta-1-42 levels, methods for reducing or preventing formation of amyloid plaques, and methods for improving cognitive function and memory retention in a subject |
04/04/2013 | WO2013049519A2 Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols |
04/04/2013 | WO2013049507A1 Antioxidant compositions for treatment of inflammation or oxidative damage |
04/04/2013 | WO2013049364A1 Resveratrol-based compounds |
04/04/2013 | WO2013049350A1 Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
04/04/2013 | WO2013049332A1 Inhibitors of monoacylglycerol lipase and methods of their use |